NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Descending) |
---|---|---|---|---|---|---|---|---|---|---|---|
69660-0202-91 | 69660-0202 | Rucaparib | Rubraca | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | May 1, 2017 | July 31, 2025 | In Use |
69660-0203-91 | 69660-0203 | Rucaparib | Rubraca | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 19, 2016 | July 31, 2025 | In Use |
70437-0240-18 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-33 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Nov. 30, 2024 | In Use |
70860-0200-50 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0205-50 | 70860-0205 | Gemcitabine Hydrochloride | Gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 31, 2017 | March 31, 2024 | In Use |
70860-0210-51 | 70860-0210 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | March 13, 2019 | Sept. 30, 2024 | In Use |
Found 10,000 results in 8 milliseconds — Export these results